Article Text

Download PDFPDF

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
  1. Yi Lin1,
  2. Thomas Atwell1,
  3. Adam Weisbrod1,
  4. Mary Maas1,
  5. Adam Armstrong1,
  6. Michael Deeds1,
  7. Peggy Bulur1,
  8. Michael Gustafson1,
  9. Zhe Zhang1,
  10. Louis Porrata1,
  11. Svetomir Markovic1,
  12. Patrick Johnston1,
  13. Ivana Micallef1,
  14. David Inwards1,
  15. Joseph Colgan1,
  16. Stephen Ansell1,
  17. Dennis Gastineau1,
  18. Allan Dietz1 and
  19. Thomas Witzig1
  1. Aff1 grid.66875.3a000000040459167XMayo Clinic Rochester MN USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


We present the preliminary results of our clinical trial testing 2 vaccine strategies in patients with indolent B cell non-Hodgkin lymphoma (NHL; NCT01239875, The primary objective is to determine the safety and feasibility of the vaccine approaches and secondary objectives are to describe clinical responses and identify corresponding immune changes.


Autologous mature dendritic cells (mDC) were manufactured from leukapheresed cells of NHL patients. For patients with tumor lymph nodes deemed amenable to cryoablation by interventional radiologist (arm A), they received cryoablation of a node and injection of mDC into the cryoablated node followed by another 1 to 7 intratumoral mDC injections. Remaining patients had a tumor excised to generate tumor lysate ex vivo. mDC were pulsed with tumor lysate during DC maturation (arm B; DC-TL). The DC-TL vaccines were injected intradermally for 4 to 8 doses. Patients are monitored for one year after vaccines for adverse events and systemic tumor response. Correlative studies include cellular immune phenotype of peripheral blood and T cell intracellular cytokine productions. Planned accrual is 10 patients per arm (total = 20).


To date, 10 patients have accrued to arm A and 5 patients to arm B. All patients tolerated vaccine treatments without major adverse events. Of the 10 evaluable patients, there were 1 CR (arm B: 1 / 4; total: 1/10) and 4 PR (arm A: 3/6; arm B: 1 / 4; total: 5/10) for an ORR of 50% for both arms (Table 1). Responses have been durable for at least 1 year. Correlative studies suggest that immune changes can be used as prognostic biomarkers to predict response. Upon stimulation, responders' T cells had increased IFN-γ and or IL-17a and lower IL-4 production than non-responder T cells. Preliminary analysis of >80 immune phenotypes using flow cytometry and hierarchical clustering suggest that, after vaccination, many components within the immune system of responders change in a different manner from the non-responders.

Patient responses


Both cryoablation and intratumoral mDC vaccination are feasible and safe in NHL. Treatment responses may correlate with immune system changes. Biosystems analysis method can be used to develop novel assays as predictive biomarkers of treatment response.